Welcome to our dedicated page for ClearPoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
ClearPoint Neuro, Inc. shareholders led by Bigger Capital Fund, LP and affiliated entities filed an amended Schedule 13G reporting their beneficial ownership of the company’s common stock. As of August 4, 2026, Bigger Capital beneficially owned 1,405,284 shares of common stock, and its general partner Bigger Capital Fund GP, LLC may be deemed to beneficially own the same amount, representing approximately 4.60% of the class.
District 2 Capital Fund LP beneficially owned 295,196 shares, and related District 2 entities may be deemed to beneficially own that stake, representing 0.96% of outstanding shares. Michael Bigger, through his roles with Bigger GP and District 2 Holdings and his personal and family holdings, may be deemed to beneficially own 2,272,980 shares, or approximately 7.45% of the outstanding common stock, while Patricia Winter holds 167,000 shares, or 0.54%. These percentages are based on 30,504,227 shares outstanding as of July 27, 2026; the filing includes customary disclaimers of beneficial ownership among the reporting persons.
ClearPoint Neuro, Inc. reported Q2 2026 total revenue of $10.9 million, up from $9.2 million in Q2 2025, and six‑month revenue of $23.0 million versus $17.7 million a year earlier. Growth was driven by neurosurgery navigation and therapy revenue of $5.6 million, up 62%, and capital equipment and software revenue of $1.3 million.
Biologics and drug delivery revenue was $4.0 million, down from $4.7 million due to a large prior‑year order that did not repeat. Gross profit was $6.7 million with a 62% gross margin. Operating loss widened to $10.2 million, and net loss to $11.3 million, or $(0.38) per share, as research and development, sales and marketing, and general and administrative expenses all increased.
At June 30, 2026, cash and cash equivalents were $29.4 million, total assets $86.7 million, and long‑term notes payable had a carrying amount of $50.2 million with an effective interest rate of 11.3%. The company recorded net cash used in operating activities of $15.0 million for the first half of 2026 and concluded its existing cash and cash equivalents are sufficient to support operations and meet obligations for at least the next twelve months from the date of issuance of these financial statements.
ClearPoint Neuro reported second quarter 2026 revenue of $10.9 million, up 18% from $9.2 million, driven by strong growth in neurosurgery navigation and therapy, which rose 62% to $5.6 million, and capital equipment and software, up 24% to $1.3 million. Biologics and drug delivery revenue declined 15% to $4.0 million as large prior-year trial-initiation orders did not repeat, though preclinical service revenue grew. Gross margin improved to 62%.
Operating expenses increased to $17.0 million, reflecting the IRRAflow acquisition and expansion of clinical and sales teams, contributing to an operating loss and a basic and diluted net loss per share of $0.38 versus $0.21 a year earlier. Cash and cash equivalents were $29.4 million at June 30, 2026, down from $45.9 million at year-end, mainly due to $15.0 million used in operating activities and $2.0 million of tax payments related to equity awards. Management now expects 2026 revenue between $48.0 million and $52.0 million.
The company highlighted multiple biopharma partners receiving positive FDA feedback on potential BLA submissions and expects 10–15 clinical trials using its technology to be enrolling in the next 18 months, with roughly 10 data readouts. ClearPoint took possession of its ClearPoint Advanced Laboratories facility, signed initial preclinical statements of work including its first GLP study, and announced a 10-year focused ultrasound drug-delivery partnership with the SONOCARE Lab in South Korea, while advancing its robotic platform and Harmony 1.0 software to expand capacity ahead of potential commercial cell and gene therapy launches around 2027.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of common stock of ClearPoint Neuro, Inc.. BlackRock reports beneficial ownership of 2,118,912 shares of common stock, representing 7.1% of the class.
BlackRock has sole voting power over 2,087,782 shares and sole dispositive power over 2,118,912 shares, with no shared voting or dispositive power. Various underlying clients have economic rights to dividends and sale proceeds, but no single client holds more than five percent of the outstanding common shares.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director R. John Fletcher received 662 shares of Common Stock as compensation. The shares were issued under the company’s incentive and non-employee director compensation plans at a value of $17.84 per share, matching the June 30, 2026 closing price. After this grant, Fletcher directly holds 131,011 shares.
Richards Timothy T. reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Timothy T. Richards received 222 shares of Common Stock as compensation. The shares were granted on June 30, 2026 under the company’s Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed under the Non-Employee Director Compensation Plan.
The shares were valued at a price of $17.84 per share, matching the closing price of ClearPoint Neuro’s stock on June 30, 2026. Following this award, Richards directly holds 87,544 shares of ClearPoint Neuro common stock, indicating this was a routine, small incremental grant rather than a large new position.
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall acquired 1,781 shares of common stock through the company’s Employee Stock Purchase Plan. These shares were purchased for $11.93 per share for the ESPP period from January 1, 2026 through June 30, 2026.
After this ESPP acquisition, Stigall directly holds a total of 110,263 shares of ClearPoint Neuro common stock. Under the ESPP terms, the purchase price was 85% of the fair market value on the first or last day of the purchase period, whichever was lower.
ClearPoint Neuro Chief Financial Officer Danilo D'Alessandro acquired 1,085 shares of common stock through the company’s Employee Stock Purchase Plan. The shares relate to the ESPP purchase period from January 1, 2026 through June 30, 2026 and were bought at $11.93 per share. After this routine compensation-related acquisition, he directly holds 103,769 shares of ClearPoint Neuro common stock.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported routine insider activity involving company common stock. He acquired 1,361 shares of common stock on June 30, 2026 as a grant/award under the company’s Employee Stock Purchase Plan (ESPP) at $11.93 per share. The ESPP purchase covered the period from January 1, 2026 through June 30, 2026, with shares bought at 85% of the lower of the fair market value on the first or last day of that period. Following this ESPP acquisition, Burnett directly owns 118,203 shares of ClearPoint Neuro common stock and indirectly has 191,388 shares held through the Joseph M. Burnett Trust dated October 20, 2022, where he serves as trustee.
ClearPoint Neuro, Inc. director and CEO Joseph Burnett reported an option exercise and related share sale in Common Stock. He exercised stock options to acquire 20,000 shares at $2.50 per share and sold 20,000 shares in an open-market transaction at a weighted average price of $19.38 per share.
Following these transactions, he holds 116,842 shares directly and 191,388 shares indirectly through the Joseph M. Burnett Trust. The filing notes the exercise and sale were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.